Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2018 - 201912020 - 20222

Settings

search.filters.applied.f.rights: search.filters.rights.info:eu-repo/semantics/closedAccessSubject: search.filters.subject.Metformin

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    The Protective Effect of Metformin Against the Noise-Induced Hearing Loss
    (2018) Kesici, Gulin Gokcen; Ocal, Fatma Ceyda Akin; Gurgen, Seren Gulsen; Erdem, Saban Remzi; Ogus, Ersin; Erbek, Hatice Seyra; Ozluoglu, Levent Naci; 0000-0003-0409-6225; 0000-0002-7537-2170; 0000-0002-9877-421X; 0000-0002-2150-0237; 30306316; AAT-2326-2021; AAJ-2370-2021; AAJ-1058-2021; AAI-8020-2021
    ObjectiveTo test the protective effect of metformin against noise-induced hearing loss.Methods24 rats were included in the study. The first group was exposed to noise only, the second group took metformin, the third group was exposed to noise and took metformin, and the fourth group was neither exposed to noise nor took metformin as control group. After measurement of baseline DPOAE and ABR of rats, the metformin group and the metformin+noise group received 300mg/kg/day metformin via gavage for 10days. On the 11th day, group 1 and group 3 were exposured to white noise at 105dB SPL for 15h. After noise exposure, DPOAE and ABR measurements of all rats were repeated on days 1st, 7th, and 21st. At the end of the study, all animals were sacrificed and cochlear tissues were separated for immunohistochemical assessments.ResultsABR threshold values and DPAOE measurements of groups 1 and 3 were deteriorated on the 1st day after noise, while deterioration in group 1 continued on 7th and 21st days, but normalized on 7th day in group 3. After immune staining, a significant immunoreaction was observed in the noise group, while the reaction in the noise+metformin group was close to the control group.ConclusionMetformin has a protective effect on noise-induced hearing loss in rats. As a conclusion, it is determined that metformin protects from permanent threshold shift in rats. It can be considered a good alternative for protecting noise-induced hearing loss.
  • No Thumbnail Available
    Item
    Evaluation of Electrodermal Activity and Anxiety Behaviors in Diabetic Rats Given Vildagliptin and Metformin
    (2022) Shawesh, Muftah; Alshareef, Mohammed; Boyuk, Gulbahar; Yigit, Ayse Arzu; Dolu, Nazan
  • No Thumbnail Available
    Item
    Prognostic Factors in Squamous Cell Carcinoma of the Vulva: a Retrospective Multicenter Study
    (2020) Kuru, Oguzhan; Akgor, Utku; Cakir, Ilker; Tosun, Ozgur; Yuksel, Ilkbal Temel; Ulker, Volkan; Meydanli, Mutlu; Sanci, Muzaffer; Gokcu, Mehmet; Topuz, Samet; Yildiz, Ferah; Sakinci, Mehmet; Salman, Mehmet Coskun; Ozgul, Nejat; Yuce, Kunter; Ayhan, Ali; AAJ-5802-2021
    The study aim to determine the clinicopathological factors for disease-free survival (DFS) and overall survival (OS) in women with vulvar cancer and to analyze the the possible effect of metformin on survival of the patients. From 2011 to 2017, medical records of 142 patients who underwent primary radical surgery for VC at 6 referral centers in Turkey were collected, retrospectively. The median age of the cohort was 67.0 years. 124 patients underwent radical surgery and inguinofemoral lymphadenectomy. The overall recurrence rate was 33.8% within a median follow-up time of 22 months. Five-year DFS and OS rates were 55.8% and 62.6%, respectively. Multivariate analysis showed surgical margin (HR:6.4, p= 0.017 for DFS; HR: 13.6, p=0.009 for OS) and lymph node metastasis (HR: 4.1, p= 0.014 for DFS; HR: 6.3, p= 0.020 for OS) were the independent prognostic factors. There was no statistically difference in DFS and OS for patients who had used metformin.